Development PipelineSGN-B6A

an investigational antibody–drug conjugate directed to Integrin Beta-6

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

SGNB6A-001: Advanced solid tumors

  • Phase 1

  • Phase 2

  • Phase 3

Program Resources

High-level synopsis of SGN-B6A and ongoing clinical trials

Detailed information about SGN-B6A clinical trials